Loading clinical trials...
Loading clinical trials...
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 6 μg HA/Strain/0.5 ml) for Children and Adolescents
Conditions
Interventions
Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml)
Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)
Start Date
October 1, 2014
Primary Completion Date
December 1, 2014
Completion Date
December 1, 2014
Last Updated
March 11, 2021
NCT04682444
NCT04431050
NCT03448705
NCT03572491
NCT01651104
NCT01879540
Lead Sponsor
Fluart Innovative Vaccine Ltd, Hungary
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions